Crosslinked HA is produced by chemically connecting individual HA polymer chains with covalent BDDE crosslinking bridges to form a 3D hydrogel network. Linear (native) HA dissolves in water, flows freely, and is rapidly degraded by hyaluronidase enzymes (HYAL1/HYAL2) within 24-48 hours. Crosslinked HA is water-insoluble — it swells to form a cohesive hydrogel that resists enzymatic degradation via steric hindrance (the 3D network physically blocks enzyme access to individual HA chain cleavage sites) and remains in place for 6-24 months. This is what makes dermal fillers last 6-18 months instead of 1-2 days. The crosslinking transforms HA from a soluble, short-lived biopolymer into an insoluble, long-residing, tissue-augmenting hydrogel — the fundamental technology behind the entire $5B+ dermal filler industry.

BDDE (1,4-butanediol diglycidyl ether) is the most widely used and clinically established HA crosslinking agent, used in FDA-approved and CE-marked dermal fillers for over 20 years (Restylane, Juvéderm, Belotero, Teosyal). It is a bifunctional epoxide — each of its two terminal epoxide rings reacts with a hydroxyl (-OH) group on the HA polysaccharide backbone (primarily N-acetyl-D-glucosamine C6 primary alcohol, also D-glucuronic acid C2/C3 secondary alcohols) to form stable ether (-C-O-C-) crosslinking bridges. The ether linkage is chemically stable under physiological conditions (pH 7.4, 37°C) — it is not hydrolyzed or enzymatically cleaved, providing permanent crosslinking for the lifetime of the hydrogel. Our manufacturing process uses pharmaceutical-grade BDDE (≥99% purity) followed by exhaustive multi-step purification: tangential flow filtration (TFF) dialysis (100 kDa MWCO membrane, 10 volumes PBS exchange), organic solvent extraction (ethyl acetate — removes hydrophobic unreacted BDDE and BDDE mono-ether byproducts), ethanol precipitation (recovers crosslinked HA while leaving water-soluble residuals in supernatant), and vacuum drying (removes volatile organics). The result: residual unreacted BDDE <2 ppm — verified by HPLC-MS/MS (triple quadrupole, MRM transition m/z 203→147, LOQ 0.1 ppm) in every batch COA. This level meets or exceeds the strictest global regulatory standards for implantable devices including ISO 10993-17 (toxicological risk assessment for leachables) and USP <1663>/<1664> (extractables and leachables assessment).

Yes. Gel content (degree of crosslinking) and swelling ratio are the two key parameters that determine the mechanical and degradation properties of the final filler/implant. We can tune gel content from 60-95% and swelling ratio from 20-80 g/g by adjusting the BDDE:HA feed ratio (typically 1:5 to 1:20 w/w), reaction pH (10-12, NaOH), temperature (40-60°C), and crosslinking duration (2-24 hours). The structure-property relationship: Higher crosslink density (higher BDDE:HA ratio, longer reaction time) → higher gel content (85-95%), lower swelling (20-40 g/g) → firmer gel (higher G′, lower tan δ), longer persistence (18-24 months) → suitable for deep volumizing fillers (cheek, chin, jawline) and structural implants. Lower crosslink density (lower BDDE:HA ratio, shorter reaction time) → lower gel content (60-80%), higher swelling (50-80 g/g) → softer gel (lower G′, higher tan δ), shorter persistence (6-12 months) → suitable for fine-line fillers (perioral, periorbital) and viscosupplements. For biphasic filler designs, we can produce different crosslink density populations that are blended to achieve target rheology (bimodal G′ distribution). Contact our technical team with your target product profile — rheology specifications (G′ at 1 Hz, tan δ, complex viscosity η*), extrusion force (N at 50 mm/min through 27G/30G needle), and persistence target — and we will recommend the optimal crosslinking specifications and provide a pilot batch for your evaluation.

No. This is the crosslinked HA raw material powder — not a finished injectable product. The finished product manufacturer performs the following downstream processing steps: (1) Hydration — swelling the powder in phosphate-buffered saline (PBS, pH 7.4) or formulation buffer to the target HA concentration (typically 15-25 mg/mL for fillers, 10-20 mg/mL for viscosupplements); (2) Particle sizing — wet milling (high-shear mixer or colloid mill) and sieving through calibrated stainless steel mesh screens to achieve the target particle size distribution (typically D50 200-500 μm for fillers); (3) Formulation — blending with lidocaine HCl (0.3% w/w for pain relief during injection), vitamins, amino acids, or other active ingredients — homogenization under vacuum to remove air bubbles; (4) Filling — aseptic filling into pre-filled glass syringes (1.0 mL BD Hypak or equivalent) with plunger stopper and tip cap under ISO 5 (Class 100) laminar flow; (5) Terminal sterilization — moist heat (autoclave 121°C, 15-20 min, validated per ISO 17665) or ethylene oxide sterilization (validated per ISO 11135). The sterilized finished product then undergoes final QC testing — sterility (USP <71>), endotoxin (<0.5 EU/device), extrusion force, rheology, particulate matter (USP <788>), and package integrity. We provide the crosslinked HA powder with complete DMF Type IV documentation, CMC data package, and ISO 10993 biocompatibility test data (cytotoxicity, sensitization, irritation, systemic toxicity, implantation — on the formulated/sterilized device) to support your finished product regulatory filing.

Every shipment includes a comprehensive pharmaceutical-grade documentation package: COA (gel content 60-95% by gravimetric gel fraction; swelling ratio 20-80 g/g; residual BDDE <2 ppm by HPLC-MS/MS MRM m/z 203→147 LOQ 0.1 ppm; bacterial endotoxin <0.05 EU/mg by LAL kinetic chromogenic method USP <85>; sterility USP <71>; HA content 85-95% by carbazole assay; heavy metals ≤10 ppm; elemental impurities Pb/As/Hg/Cd per USP <232>/ICH Q3D; microbial panel USP <61>/<62>), MSDS, DMF Type IV Letter of Authorization (cross-reference to your ANDA/NDA/510(k)/CE marking submission), CMC (Chemistry, Manufacturing, Controls) Data Package — manufacturing process flow diagram, critical process parameters (CPPs) and critical quality attributes (CQAs), BDDE feed ratio and purification steps, in-process controls, batch analysis data (minimum 3 consecutive lots for regulatory submission), and container closure system description, ISO 10993 Biocompatibility Data (cytotoxicity ISO 10993-5, sensitization ISO 10993-10, irritation ISO 10993-23, systemic toxicity ISO 10993-11, implantation ISO 10993-6 — tested on hydrated/sterilized finished device equivalent), BSE/TSE-Free Statement (no animal-derived materials — HA sourced from fermentation, BDDE synthetic), Stability Data (25°C/60%RH 36-month real-time; 40°C/75%RH 6-month accelerated; gel content, swelling ratio, residual BDDE, sterility, and endotoxin re-verified at 3/6/12/24/36 months), and Complete Lot Traceability from HA fermentation batch → crosslinking reaction batch → purification batch → finished powder batch. Free sample available for qualified, regulatory-compliant B2B buyers. MOQ: 10 g for pilot evaluation; 100 g for commercial supply. All documents in English.